Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil Makes Drug Prices Transparent To Strengthen Hand In Pricing Talks

Executive Summary

Brazil wants to drive competition and lower drug prices by obliging health authorities to publish the prices paid for all drugs bought by the national health system. A voluntary system has already helped save $1bn and cut the price of Gilead’s Sovaldi by around 30%.

You may also be interested in...



Brazil Prepares To Make Its Own Sovaldi As Regulator Opposes Patent Application

Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.

German Insurers Want End To Free Pricing In Amnog Review

Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.

Investors Spooked By High Prices For Advanced Therapies

To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel